Serca–VivarRios CaBI19 vaccine: Difference between revisions
Jump to navigation
Jump to search
(Created page with "{{Region icon MusgorociaSC}} {{under construction}} {{Infobox product | title = Serca–VivarRios CaBI19 vaccine | image = Cabi vaccine2.png | image_size...") |
m (page inactive; removing tag) |
||
| (4 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{Region icon MusgorociaSC}} | {{Region icon MusgorociaSC}} | ||
{{Infobox product | {{Infobox product | ||
| title = Serca–VivarRios CaBI19 vaccine | | title = Serca–VivarRios CaBI19 vaccine | ||
| Line 15: | Line 14: | ||
| last production = | | last production = | ||
| models = CabiShield | | models = CabiShield | ||
| website = | | website = {{url|https://www.cabishield.cs|cabishield.cs}} | ||
| notes = | | notes = | ||
}} | }} | ||
The '''Serca–VivarRios CaBI19 vaccine''', also sold under the brand name '''CabiShield''', is a [[Carloso|Carlosian]] toxoid-based vaccine being developed against the [[CaBI19 pandemic|''Clostroides abaddoni'' bacterial infection 2019]] (CaBI19) disease. It is an evolution of efforts to develop a vaccine for ''Clostridioides difficile'' infection (CDI). Interim results indicate an efficacy of 95% against CaBI19. | |||
==Notes== | ==Notes== | ||
| Line 23: | Line 23: | ||
==See also== | ==See also== | ||
*[[Serca–VivarRios COVID-19 vaccine]] | *[[Serca–VivarRios COVID-19 vaccine]] | ||
==External links== | |||
*[https://forum.nationstates.net/viewtopic.php?p=38597575#p38597575 VivarRios: Results of CaBI19 vaccine trials 'promising'] — ''RTC News'' | |||
[[Category:Carloso]] | |||
Latest revision as of 12:15, 31 July 2023
 | |
| Type | Toxoid-based vaccine |
|---|---|
| Inventor | Serca Circuit University VivarRios Pharmaceuticals |
| Manufacturer | VivarRios Pharmaceuticals |
| Available | In Phase III trials in Carloso and some other countries |
| Models made | CabiShield |
| Website | cabishield.cs |
The Serca–VivarRios CaBI19 vaccine, also sold under the brand name CabiShield, is a Carlosian toxoid-based vaccine being developed against the Clostroides abaddoni bacterial infection 2019 (CaBI19) disease. It is an evolution of efforts to develop a vaccine for Clostridioides difficile infection (CDI). Interim results indicate an efficacy of 95% against CaBI19.
Notes
See also